Shopping Cart 0
Cart Subtotal
USD 0

Protalix BioTherapeutics Inc (PLX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company's marketed product, Taliglucerase (taliglucerase alfa) is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of Fabry disease; cystic fibrosis and gaucher disease. Protalix develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology: ProCellEx System. Protalix is headquartered in Carmiel, Israel

Protalix BioTherapeutics Inc (PLX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Protalix Enters Into Technology Transfer Agreement With Oswaldo Cruz Foundation For Uplyso 10

Licensing Agreements 12

Chiesi Farmaceutici Expands Licensing Agreement with Protalix 12

Equity Offering 14

Protalix BioTherapeutics Raises USD10 Million in Private Placement of Shares 14

Protalix BioTherapeutics Completes Public Offering Of Common Stock For USD 27 Million 15

Debt Offering 17

Protalix BioTherapeutics Raises USD22.5 Million in Private Placement of Notes 17

Protalix BioTherapeutics Completes Private Placement Of Notes Due 2018 For USD 69 Million 18

Acquisition 19

Protalix BioTherapeutics Mulls Offering Itself For Sale 19

Protalix BioTherapeutics Inc-Key Competitors 20

Protalix BioTherapeutics Inc-Key Employees 21

Protalix BioTherapeutics Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Nov 07, 2018: Protalix BioTherapeutics reports 2018 third quarter results and provides corporate update 23

Aug 09, 2018: Protalix BioTherapeutics reports 2018 second quarter results and provides corporate update 24

May 09, 2018: Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update 25

Mar 06, 2018: Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update 26

Nov 08, 2017: Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update 27

Aug 09, 2017: Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update 28

May 10, 2017: Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update 30

Mar 16, 2017: Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update 31

Jan 09, 2017: Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017 32

Corporate Communications 33

Aug 13, 2018: Protalix Biotherapeutics names David Granot as board director 33

Clinical Trials 34

Jan 03, 2017: Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase) for the Treatment of Cystic Fibrosis 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Protalix BioTherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Protalix Enters Into Technology Transfer Agreement With Oswaldo Cruz Foundation For Uplyso 10

Chiesi Farmaceutici Expands Licensing Agreement with Protalix 12

Protalix BioTherapeutics Raises USD10 Million in Private Placement of Shares 14

Protalix BioTherapeutics Completes Public Offering Of Common Stock For USD 27 Million 15

Protalix BioTherapeutics Raises USD22.5 Million in Private Placement of Notes 17

Protalix BioTherapeutics Completes Private Placement Of Notes Due 2018 For USD 69 Million 18

Protalix BioTherapeutics Mulls Offering Itself For Sale 19

Protalix BioTherapeutics Inc, Key Competitors 20

Protalix BioTherapeutics Inc, Key Employees 21

Protalix BioTherapeutics Inc, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Protalix BioTherapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.